Drug firm Caplin Point Laboratories today said US health regulator would conduct a prior approval inspection of its Gummidopoondi facility in Chennai in October.
"The United States Food and Drug Administration (USFDA) inspection is to be conducted for the company's sterile injectable site located near Gummidopoondi in third week of October," Caplin Point Laboratories said in a filing to BSE.
This Prior Approval Inspection (PAI) is in relation to an injectable product abbreviated new drug application (ANDA) being submitted with USFDA, it added.
Also Read
The company holds over 2,000 product licenses across the globe.
Shares of Caplin Point Laboratories today closed at Rs 1,315.05 on BSE, down 0.55 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
